Heparin and Liver Heparan Sulfate Can Rescue Hepatoma Cells from Topotecan Action

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Dudás, József ^a,b   Bocsi, József ^b   Fullár, Alexandra ^b   Baghy, Kornélia ^b   Füle, Tibor ^b   Kudaibergenova, Saule ^a,c   Kovalszky, Ilona ^b  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c ASFENDIYAROV KAZAKH NATIONAL MEDICAL UNIVERSITY   (Kazakhstan)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE; HEPARAN SULFATE; HEPARIN; TOPOTECAN; DNA; TOP1 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; BINDING COMPETITION; CELL COUNT; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; DNA BINDING; DRUG EFFICACY; ENZYME ACTIVITY; HEPATOCELLULAR CARCINOMA CELL LINE; HEPATOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CANCER; LIVER CELL CARCINOMA; LIVER HISTOLOGY; PROTEIN CLEAVAGE; S PHASE CELL CYCLE CHECKPOINT; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL PROLIFERATION; DRUG EFFECTS; HEPG2 CELL LINE; LIVER; LIVER NEOPLASMS; METABOLISM; PATHOLOGY;

CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL PROLIFERATION; DNA TOPOISOMERASES, TYPE I; DNA, NEOPLASM; HEP G2 CELLS; HEPARIN; HEPARITIN SULFATE; HUMANS; LIVER; LIVER NEOPLASMS; TOPOTECAN;

EID: 84935873116     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/765794     Document Type: Article

References (47)

1. M. Bernfield, M. Götte, P. W. Park et al., "Functions of cell surface heparan sulfate proteoglycans, " Annual Review of Biochemistry, vol. 68, pp. 729-777, 1999.
2. X. Lin and N. Perrimon, "Role of heparan sulfate proteoglycans in cell-cell signaling in Drosophila, " Matrix Biology, vol. 19, no. 4, pp. 303-307, 2000.
3. S. Ashikari-Hada, H. Habuchi, Y. Kariya, N. Itoh, A. H. Reddi, and K. Kimata, "Characterization of growth factor-binding structures in heparin/heparan sulfate using an octasaccharide library, The Journal of Biological Chemistry, vol. 279, no. 13, pp. 12346-12354, 2004.
4. M. Kan, X. Wu, F. Wang, and W. L. McKeehan, "Specificity for fibroblast growth factors determined by heparan sulfate in a binary complex with the receptor kinase, " Journal of Biological Chemistry, vol. 274, no. 22, pp. 15947-15952, 1999.
5. L. Pellegrini, "Role of heparan sulfate in fibroblast growth factor signalling: A structural view, " Current Opinion in Structural Biology, vol. 11, no. 5, pp. 629-634, 2001.
6. A. Sebestyén, M. Gallai, T. Knittel, T. Ambrust, G. Ramadori, and I. Kovalszky, "Cytokine regulation of syndecan expression in cells of liver origin, " Cytokine, vol. 12, no. 10, pp. 1557-1560, 2000.
7. B. Péterfia, T. Füle, K. Baghy et al., "Syndecan-1 enhances proliferation, migration and metastasis of HT-1080 cells in cooperation with syndecan-2, " PLoS ONE, vol. 7, no. 6, Article ID e39474, 2012.
8. S. Ricard-Blum, O. Féraud, H. Lortat-Jacob et al., "Characterization of endostatin binding to heparin and heparan sulfate by surface plasmon resonance and molecular modeling: A role of divalent cations, The Journal of Biological Chemistry, vol. 279, no. 4, pp. 2927-2936, 2004.
9. B. Casu, A. Naggi, and G. Torri, "Heparin-derived heparan sulfate mimics to modulate heparan sulfate-protein interaction in inflammation and cancer, " Matrix Biology, vol. 29, no. 6, pp. 442-452, 2010.
10. D. Spillmann, D. Witt, and U. Lindahl, "Defining the interleukin-8-binding domain of heparan sulfate, " The Journal of Biological Chemistry, vol. 273, no. 25, pp. 15487-15493, 1998.
11. H. Lortat-Jacob, A. Grosdidier, and A. Imberty, "Structural diversity of heparan sulfate binding domains in chemokines, " Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 3, pp. 1229-1234, 2002.
12. C. Faye, C. Moreau, E. Chautard et al., "Molecular interplay between endostatin, integrins, and heparan sulfate, " The Journal of Biological Chemistry, vol. 284, no. 33, pp. 22029-22040, 2009.
13. M. Ishihara, N. S. Fedarko, and H. E. Conrad, "Transport of heparan sulfate into the nuclei of hepatocytes, " Journal of Biological Chemistry, vol. 261, no. 29, pp. 13575-13580, 1986.
14. H. Hausser, O. Witt, and H. Kresse, "Influence of membraneassociated heparan sulfate on the internalization of the small proteoglycan decorin, " Experimental Cell Research, vol. 208, no. 2, pp. 398-406, 1993.
15. A. V. Dix, L. Fischer, S. Sarrazin, C.P.H.Redgate, J.D.Esko, and Y. Tor, Cooperative, heparan sulfate-dependent cellular uptake of dimeric guanidinoglycosides, ChemBioChem, vol. 11, no. 16, pp. 23022310, 2010.
16. J. Tímár, K. Lapis, J. Dudás, A. Sebestyén, L. Kopper, and I. Kovalszky, "Proteoglycans and tumor progression: A Janus-faced molecules with contradictory functions in cancer, " Seminars in Cancer Biology, vol. 12, pp. 173-186, 2002.
17. J. Dudas, G. Ramadori, T. Knittel et al., "Effect of heparin and liver heparan sulphate on interaction of HepG2-derived transcription factors and their cis-acting elements: A altered potential of hepatocellular carcinoma heparan sulphate, " Biochemical Journal, vol. 350, part 1, pp. 245-251, 2000.
18. D. Liu, Z. Shriver, G. Venkataraman, Y. El Shabrawi, and R. Sasisekharan, "Tumor cell surface heparan sulfate as cryptic promoters or inhibitors of tumor growth and metastasis, " Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 2, pp. 568-573, 2002.
19. S. J. Busch, G. A. Martin, R. L. Barnhart, M. Mano, A. D. Cardin, and R. L. Jackson, "Trans-repressor activity of nuclear glycosaminoglycans on fos and jun/AP-1 oncoprotein-mediated transcription, " Journal of Cell Biology, vol. 116, no. 1, pp. 31-42, 1992.
20. F. Cheng, P. Petersson, Y. Arroyo-Yanguas, and G.Westergren- Thorsson, "Differences in the uptake and nuclear localization of anti-proliferative heparan sulfate between human lung fibroblasts and human lung carcinoma cells, " Journal of Cellular Biochemistry, vol. 83, no. 4, pp. 597-606, 2001.
21. I. Kovalszky, J. Dudás, J. Oláh-Nagy et al., "Inhibition of DNA topoisomerase I activity by heparan sulfate and modulation by basic fibroblast growth factor, Molecular and Cellular Biochemistry, vol. 183, pp. 11-23, 1998.
22. I. Kovalszky, A. Hjerpe, and K. Dobra, "Nuclear translocation of heparan sulfate proteoglycans and their functional significance, " Biochimica et Biophysica Acta, vol. 1840, no. 8, pp. 2491-2497, 2014.
23. M. T. Tomicic and B. Kaina, "Topoisomerase degradation, DSB repair, p53 and IAPs in cancer cell resistance to camptothecinlike topoisomerase I inhibitors, " Biochimica et Biophysica Acta, vol. 1835, no. 1, pp. 11-27, 2013.
24. B. E. Loveland , T. G. Johns, L. R. Mackay, F. Vaillant, Z.-X. Wang, and P. J. Hertzog, "Validation of the MTT dye assay for enumeration of cells in proliferative and antiproliferative assays, " Biochemistry International, vol. 27, no. 3, pp. 501-510, 1992.
25. G. H. Hogeboom, "Fractionation of cell components of animal tissues, " Methods in Enzymology, vol. 1, no. C, pp. 16-19, 1955.
26. M. Duguet, C. Lavenot, F. Harper, G. Mirambeau, and A.-M. D. Recondo, "DNA topoisomerases fromrat liver: A physiological variations, " Nucleic Acids Research, vol. 11, no. 4, pp. 1059-1075, 1983.
27. H. Takano, K. Kohno, M. Ono, Y. Uchida, and M. Kuwano, "Increased phosphorylation of DNA topoisomerase II in etoposide-resistant mutants of human cancer KB cells, " Cancer Research, vol. 51, no. 15, pp. 3951-3957, 1991.
28. R.W. Farndale, C. A. Sayers, and A. J. Barrett, "A direct spectrophotometric microassay for sulfated glycosaminoglycans in cartilage cultures, " Connective Tissue Research, vol. 9, no. 4, pp. 247-248, 1982.
29. A. K. Larsen, L. Grondard, J. Couprie et al., "The antileukemic alkaloid fagaronine is an inhibitor of DNA topoisomerases I and II, " Biochemical Pharmacology, vol. 46, no. 8, pp. 1403-1412, 1993.
30. F. Fleury, A. Sukhanova, A. Ianoul et al., "Molecular determinants of site-specific inhibition of human DNA topoisomerase I by fagaronine and ethoxidine. Relation to DNA binding, " The Journal of Biological Chemistry, vol. 275, no. 5, pp. 3501-3509, 2000.
31. K. Lapis, I. Kavalsky, and A. Jeney, "Alterations of glycosaminoglycans in human liver and kidney tumors, " The Tokai Journal of Experimental and Clinical Medicine, vol. 15, pp. 155-165, 1990.
32. I. Kovalszky, G. Pogany, G.Molnar et al., "Altered glycosaminoglycan composition in reactive and neoplastic human liver, " Biochemical and Biophysical Research Communications, vol. 167, no. 3, pp. 883-890, 1990.
33. A. A.Khorana, A. Sahni, O.D.Altland , and C.W. Francis, "Heparin inhibition of endothelial cell proliferation and organization is dependent onmolecularweight, " Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 11, pp. 2110-2115, 2003.
34. M. Fannon, K. E. Forsten, and M.A.Nugent, "Potentiation and inhibition of bFGF binding by heparin: A model for regulation of cellular response, " Biochemistry, vol. 39, no. 6, pp. 1434-1445, 2000.
35. J. Folkman, R. Langer, R. J. Linhardt, C. Haudenschild, and S. Taylor, "Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone, " Science, vol. 221, no. 4612, pp. 719-725, 1983.
36. E. M. Stewart, X. Liu, G. M. Clark, R. M. I. Kapsa, and G. G. Wallace, "Inhibition of smoothmuscle cell adhesion and proliferation on heparin-doped polypyrrole, " Acta Biomaterialia, vol. 8, no. 1, pp. 194-200, 2012.
37. R. Sasisekharan and G. Venkataraman, "Heparin and heparan sulfate: A biosynthesis, structure and function, " Current Opinion in Chemical Biology, vol. 4, no. 6, pp. 626-631, 2000.
38. Y. Liang, M. Häring, P. J. Roughley, R. K. Margolis, and R. U. Margolis, "Glypican and biglycan in the nuclei of neurons and glioma cells: A presence of functional nuclear localization signals and dynamic changes in glypican during the cell cycle, " Journal of Cell Biology, vol. 139, no. 4, pp. 851-864, 1997.
39. E. Hsia, T. P. Richardson, and M. A. Nugent, "Nuclear localization of basic fibroblast growth factor is mediated by heparan sulfate proteoglycans through protein kinase C signaling, " Journal of Cellular Biochemistry, vol. 88, no. 6, pp. 1214-1225, 2003.
40. I. Vlodavsky and Y. Friedmann, "Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis, " The Journal of Clinical Investigation, vol. 108, no. 3, pp. 341-347, 2001.
41. I. Vlodavsky, M. Elkin, G. Abboud-Jarrous et al., "Heparanase: A one molecule with multiple functions in cancer progression, " Connective Tissue Research, vol. 49, no. 3-4, pp. 207-210, 2008.
42. G. E. Bertolesi, H. Y. Su, G. Michaiel, S. M. Dueck, C. L. Hehr, and S. Mcfarlane, "Two promoters with distinct activities in different tissues drive the expression of heparanase in Xenopus, " Developmental Dynamics, vol. 240, no. 12, pp. 2657-2672, 2011.
43. H. Engelberg, "Actions of heparin thatmay affect the malignant process, " Cancer, vol. 85, pp. 257-272, 1999.
44. K. Ishii, S. Futaki, H. Uchiyama, K. Nagasawa, and T. and oh, "Mechanism of inhibition of mammaliand NA topoisomerase I by heparin, " Biochemical Journal, vol. 241, no. 1, pp. 111-119, 1987.
45. S. W. Warmann, J. Fuchs, L. Wilkens, K. F. Gratz, D. von Schweinitz, and H. Mildenberger, "Successful therapy of subcutaneously growing human hepatoblastoma xenografts with topotecan, " Medical and Pediatric Oncology, vol. 37, no. 5, pp. 449-454, 2001.
46. K. W. McCrudden, A. Yokoi, A. Thosani et al., "Topotecan is anti-angiogenic in experimental hepatoblastoma, " Journal of Pediatric Surgery, vol. 37, no. 6, pp. 857-861, 2002.
47. G. Y. Lee, B.-S. Kim, Y. T. Seo et al., "Phase II study to topotecan and cisplatin in advanced hepatocellular carcinoma, " The Korean Journal of Internal Medicine, vol. 18, no. 2, pp. 104-108, 2003.